Bayer AG (BAYN) PT Set at €125.00 by UBS AG
Bayer AG (FRA:BAYN) received a €125.00 ($145.35) target price from stock analysts at UBS AG in a report released on Monday. The firm currently has a “buy” rating on the healthcare company’s stock. UBS AG’s target price would indicate a potential upside of 9.55% from the company’s previous close.
BAYN has been the subject of several other reports. S&P Global set a €126.00 ($146.51) target price on shares of Bayer AG and gave the stock a “buy” rating in a research note on Thursday, October 26th. Independent Research GmbH set a €120.00 ($139.53) target price on shares of Bayer AG and gave the stock a “neutral” rating in a research note on Wednesday, August 23rd. equinet AG set a €118.00 ($137.21) target price on shares of Bayer AG and gave the stock a “buy” rating in a research note on Friday, October 13th. BNP Paribas set a €130.00 ($151.16) target price on shares of Bayer AG and gave the stock a “buy” rating in a research note on Monday, September 25th. Finally, Deutsche Bank AG set a €124.00 ($144.19) target price on shares of Bayer AG and gave the stock a “buy” rating in a research note on Monday, October 16th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the stock. Bayer AG has a consensus rating of “Buy” and a consensus target price of €121.59 ($141.38).
Shares of Bayer AG (BAYN) opened at €114.10 ($132.67) on Monday. Bayer AG has a 12 month low of €85.72 ($99.67) and a 12 month high of €123.82 ($143.98).
WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/08/bayer-ag-bayn-pt-set-at-125-00-by-ubs-ag-2.html.
About Bayer AG
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Stock Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related stocks with our FREE daily email newsletter.